Drugs / AL58805
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07179081 | Dec 2020 → Jan 2026 overdue | — | Advenchen Laboratories, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AL58805 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07179081 ↗ |
| Route | Oral | “Oral,Multiple administrations, once or twice daily（20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID；）” NCT07179081 ↗ |